🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “Lux” Clear

  1. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    2 trials

  2. Dexlansoprazole MR

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    4 trials

  3. Dexlansoprazole MR

    Takeda

    Esophagitis, Reflux

    phase 3 small molecule completed

    5 trials

  4. Dexlansoprazole MR QD

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    1 trial

  5. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule terminated

    2 trials

  6. LANSOPRAZOLE, LANSOPRAZOLE, Placebo to match lansoprazole high dose, Linaprazan glurate, Placebo to match Lansoprazole low dose, Placebo to match Linaprazan Glurate

    Lacuna Pharma Pty Ltd

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  7. Lansoprazole microgranules suspension

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  8. New thickened formula

    United Therapeutics Europe Ltd

    Gastroesophageal Reflux

    phase 3 other completed

    1 trial

  9. Pantoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule completed

    2 trials

  10. Placebo

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  11. Placebo to match Linaprazan glurate 50mg, Placebo to match Lansoprazole 30 mg, Linaprazan glurate, LANSOPRAZOLE

    Lacuna Pharma Pty Ltd

    Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)

    phase 3 small molecule active

    1 trial

  12. TAK-438

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  13. Tapentadol IR 50 mg

    Janssen Cilag International NV

    Hallux Valgus

    phase 3 small molecule completed

    1 trial

  14. Vonoprazan

    Phathom Pharmaceuticals

    Non-Erosive Gastro-Esophageal Reflux Disease

    phase 3 small molecule completed

    2 trials

  15. ADX10059

    Addex Therapeutics

    Gastroesophageal Reflux

    phase 2 small molecule completed

    2 trials

  16. DEGARELIX, -, RELUGOLIX, ABIRATERONE, DEGARELIX, Luxdegalutamide, ABIRATERONE, ABIRATERONE, Abiraterone, ENZALUTAMIDE, ABIRATERONE, Enzalutamide

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  17. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 2 small molecule active

    1 trial

  18. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  19. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial

  20. Liposome bupivacaine

    Pacira Ireland Limited

    Hallux Valgus (Bunions)

    phase 2 small molecule completed

    1 trial

  21. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  22. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  23. MHS-1031

    CATALYST PHARMACEUTICALS, INC.

    Gastroesophageal Reflux

    phase 2 small molecule active

    1 trial

  24. SPD557

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources